Please assess the completion status of the following clinical trial:

Trial Title: Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with T2DM inadequately controlled with non-insulin, non-injectable anti-hyperglycemic drug(s) and for whom the Investigator/treating physicians has decided that basal insulin is appropriate.~* Signed written informed consent.~Exclusion criteria:~* Glycated hemoglobin A1c (HbA1c) \<7.0% (\<53 mmol/mol) or \>11% (97 mmol/mol) at screening.~* Age \<18 years at the time of screening.~* Body Mass Index (BMI) \>40 kg/m2.~* Diabetes other than T2DM.~* History of T2DM for less than 1 year before screening.~* Less than 6 months anti-hyperglycemic treatment before screening.~* Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit.~* Previous treatment with Glucagon Like Peptide-1 (GLP-1) agonist.~* Patients receiving only non-insulin anti-hyperglycemic drugs not approved for combination with insulin according to local labeling/local treatment guidelines and/or sulfonylurea or glinides.~* Current or previous insulin use except for a maximum of 8 consecutive days and a total of 14 days (eg, acute illness, surgery) during the last year prior to screening.~* Any contraindication to insulin glargine (Lantus) according to the National Product labeling or any excipients.~* Any contraindication to the mandatory background non-insulin anti-hyperglycemic medication according to the respective National Product labeling.~* Latest eye examination by an ophthalmologist \>12 months prior to inclusion.~* More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine U300 (Type: EXPERIMENTAL): Once daily subcutaneous injection for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).